Screener
Twist Bioscience Corporation TWST Restructuring Charges
Discontinued — last reported Q4 '25
Restructuring Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCosts.
The source filing: Twist Bioscience Corporation’s 10-K, filed November 17, 2025.
- Filed
- Nov 17, 2025
- Fiscal year
- FY2025
- Accession
- 0001581280-25-000025
| (In thousands, except per share data) | Year ended September 30, 2025 | Year ended September 30, 2024 | Year ended September 30, 2023 |
|---|---|---|---|
| Cost of revenues | $185,570 | $179,625 | $155,380 |
| Research and development expenses | 80,285 | 90,852 | 106,894 |
| Selling, general and administrative expenses | 246,976 | 218,398 | 189,738 |
| Restructuring and other costs | — | — | 9,384 |
| Change in fair value of contingent considerations and holdbacks | — | — | (5,913) |
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
Item 8. tatements and
FAQ
- What is Twist Bioscience Corporation's restructuring charges?
- Twist Bioscience Corporation (TWST) reported restructuring charges of $0 in Q3 2025.
- What does restructuring charges mean?
- One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.
Ask your AI about Twist Bioscience Corporation's restructuring charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude